Understanding why some triple-negative breast cancer patients don't respond to chemotherapy
Investigating mechanisms of chemoresistance in triple-negative breast cancer
This study is looking into why some patients with triple-negative breast cancer don’t respond well to chemotherapy, focusing on how the tumor's surroundings and certain proteins might be making it harder for treatments to work, with the hope of finding better ways to help patients in the future.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Tufts University Medford NIH-funded |
| Lab location | 1 site (Boston, UNITED STATES) |
| Project ID | NIH-11001835 on NIH RePORTER |
What this research studies
This research investigates the reasons behind chemoresistance in patients with triple-negative breast cancer (TNBC), a type of cancer that often does not respond well to standard chemotherapy. The study focuses on how the tumor's microenvironment and specific proteins contribute to this resistance, potentially leading to treatment failure and cancer recurrence. By using advanced 3-D modeling techniques, researchers aim to uncover the mechanisms that protect tumor cells from chemotherapy and promote metastasis. Patients may benefit from insights that could lead to improved treatment strategies tailored to overcome these challenges.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with triple-negative breast cancer who are undergoing or have undergone chemotherapy.
Not a fit: Patients with non-triple-negative breast cancer or those who have not received chemotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for triple-negative breast cancer, improving survival rates and reducing recurrence.
How similar studies have performed: Previous research has shown promising results in understanding chemoresistance in cancer, indicating that this approach has potential for success.
Where this research is happening
Boston, UNITED STATES
- Tufts University Medford — Boston, United States (Active)
Researchers
- Principal investigator: Oudin, Madeleine Julie — Tufts University Medford
- Study coordinator: Oudin, Madeleine Julie
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.